INM InMed Pharmaceuticals Inc.
Stock · NasdaqCM · Canada · Healthcare · CA4576378091
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by InMed Pharmaceuticals Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:52. Information, not advice.
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 10 Feb 2027 08:00 | — | — | — | Upcoming |
| 15 Nov 2022 06:00 | -108.50 | -107.86 | +0.6% | In line |
| 23 Sep 2022 12:00 | -142.50 | -118.83 | +16.6% | Beat |
| 13 May 2022 07:00 | -159.50 | -161.65 | -1.4% | Miss |
| 14 Feb 2022 16:00 | -149.50 | -197.45 | -32.1% | Miss |
| 10 Nov 2021 07:00 | -222.00 | -155.49 | +30.0% | Beat |
| 24 Sep 2021 07:00 | -212.00 | -260.24 | -22.8% | Miss |
| 13 May 2021 06:00 | -152.50 | -205.00 | -34.4% | Miss |
| 11 Feb 2021 07:00 | -153.50 | -185.00 | -20.5% | Miss |
| 08 Sep 2020 07:00 | -3,300.00 | -11,050.00 | -234.9% | Miss |
| 14 May 2020 07:00 | -3,300.00 | -3,300.00 | 0.0% | In line |
| 14 Feb 2020 07:00 | -3,300.00 | -3,300.00 | 0.0% | In line |
| 08 Nov 2019 07:00 | -3,300.00 | -3,300.00 | 0.0% | In line |
| 19 Sep 2019 07:00 | -3,300.00 | -3,300.00 | 0.0% | In line |
| 15 May 2019 07:00 | -1,650.00 | -3,300.00 | -100.0% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2026 | 0 | — | -12.6M | — | -31.20 | +62.7% | -8.6M |
| 2025 | 0 | -100.0% | -8.2M | — | -83.60 | +58.6% | -8.1M |
| 2024 | 4.6M | +11.2% | -7.7M | -166.9% | -202.00 | +68.9% | -7M |
| 2023 | 4.1M | — | -7.9M | -192.2% | -650.00 | — | -7.4M |
| 2022 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 02 Dec 2024 – 06 Dec 2024 | 43.00 | 64.00 | 42.00 | 55.00 | +28.21% | 32,570 | |
| 25 Nov 2024 – 29 Nov 2024 | 46.20 | 49.80 | 42.00 | 42.90 | -7.94% | 8,140 | |
| 18 Nov 2024 – 22 Nov 2024 | 42.80 | 49.90 | 36.50 | 46.60 | +8.85% | 21,800 | |
| 11 Nov 2024 – 15 Nov 2024 | 48.60 | 54.10 | 41.40 | 42.81 | -9.30% | 41,171 | |
| 04 Nov 2024 – 08 Nov 2024 | 52.80 | 54.80 | 43.00 | 47.20 | -9.58% | 9,477 | |
| 28 Oct 2024 – 01 Nov 2024 | 68.80 | 71.60 | 52.00 | 52.20 | -21.62% | 30,982 | |
| 21 Oct 2024 – 25 Oct 2024 | 46.00 | 71.60 | 45.60 | 66.60 | +38.75% | 62,640 | |
| 14 Oct 2024 – 18 Oct 2024 | 40.80 | 51.00 | 38.40 | 48.00 | +14.29% | 12,866 | |
| 07 Oct 2024 – 11 Oct 2024 | 41.60 | 43.80 | 40.20 | 42.00 | +3.96% | 2,717 | |
| 30 Sep 2024 – 04 Oct 2024 | 48.00 | 50.80 | 40.00 | 40.40 | -12.93% | 4,755 | |
| 23 Sep 2024 – 27 Sep 2024 | 50.00 | 52.00 | 44.20 | 46.40 | -12.45% | 7,304 | |
| 16 Sep 2024 – 20 Sep 2024 | 51.00 | 55.80 | 50.00 | 53.00 | +1.53% | 9,032 | |
| 09 Sep 2024 – 13 Sep 2024 | 53.80 | 68.00 | 51.20 | 52.20 | -2.25% | 61,576 | |
| 03 Sep 2024 – 06 Sep 2024 | 71.40 | 74.00 | 50.00 | 53.40 | -24.79% | 28,334 | |
| 26 Aug 2024 – 30 Aug 2024 | 82.00 | 93.80 | 67.20 | 71.00 | -10.80% | 36,404 | |
| 19 Aug 2024 – 23 Aug 2024 | 28.00 | 157.00 | 28.00 | 79.60 | +184.29% | 1,806,760 | |
| 12 Aug 2024 – 16 Aug 2024 | 28.60 | 31.60 | 27.20 | 28.00 | 0.00% | 7,830 | |
| 05 Aug 2024 – 09 Aug 2024 | 31.00 | 31.80 | 24.20 | 28.00 | -17.65% | 25,067 | |
| 29 Jul 2024 – 02 Aug 2024 | 56.80 | 57.00 | 32.40 | 34.00 | -41.18% | 84,356 | |
| 22 Jul 2024 – 26 Jul 2024 | 51.40 | 60.20 | 47.00 | 57.80 | +9.06% | 121,790 | |
| 15 Jul 2024 – 19 Jul 2024 | 51.40 | 57.20 | 50.20 | 53.00 | 0.00% | 12,840 | |
| 08 Jul 2024 – 12 Jul 2024 | 50.40 | 57.00 | 48.00 | 53.00 | +0.76% | 16,180 | |
| 01 Jul 2024 – 05 Jul 2024 | 53.00 | 54.00 | 48.20 | 52.60 | -1.13% | 4,603 | |
| 24 Jun 2024 – 28 Jun 2024 | 50.00 | 59.00 | 48.20 | 53.20 | +4.72% | 19,958 | |
| 17 Jun 2024 – 21 Jun 2024 | 44.80 | 61.40 | 42.40 | 50.80 | +11.89% | 60,518 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics (opens in a new tab) 06 Nov 2026 21:05
- InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI" (opens in a new tab) 05 Nov 2026 21:01
- InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation (opens in a new tab) 04 Nov 2026 21:51
- InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update (opens in a new tab) 03 Nov 2026 12:30
- InMed Pharmaceuticals Q1 EPS $(0.36) Up From $(0.46) YoY (opens in a new tab) Benzinga · 03 Nov 2026 10:03
- InMed Announces Share Consolidation in Connection with Proposed Merger (opens in a new tab) 02 Nov 2026 21:15
- INM Stock Alert: What to Know as InMed, Mentari Announce Merger (opens in a new tab) Barchart · 20 May 2026 18:01
- InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM) (opens in a new tab) InvestorsHub · 19 May 2026 15:37
- A migraine drugmaker heads to the public markets through reverse merger (opens in a new tab) BioPharma Dive · 19 May 2026 12:19
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 13.21 USD
- Market cap
- 8.5M
- Exchange
- NasdaqCM
- Country
- Canada
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 3.5 / 10 No figures for this part: it counts as a cautious 35%. | — |
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -924.8× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 60% of the figures (grade C). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -2.49× | Weak | 14.89× |
| Price / book | -71.38× | Weak | 3.8× |
| EV / EBITDA | -8.53× | Weak | 12.61× |
| Free cash flow yield | -31.9% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 58.6% |
| Operating margin | 0% | Weak | 7.6% |
| Net margin | 0% | Weak | 2.7% |
| Return on equity | -222.1% | Weak | 5.7% |
| Return on assets | -85.6% | Weak | 3.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0× | Good | 0.48× |
| Interest cover | -924.78× | Weak | 2.65× |
| Current ratio | 0.5× | Weak | 2.36× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow INM and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.